Trial Profile
A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression (CheckMate 436: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 436)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Sep 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary)
- Indications B-cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Marginal zone B-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sezary syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms CheckMate 436
- Sponsors Bristol-Myers Squibb
- 21 Sep 2023 This trial has been discontinued in Spain, according to European Clinical Trials Database record.
- 07 Feb 2023 Status changed from active, no longer recruiting to completed.
- 08 Dec 2020 Results (n=10) evaluating the efficacy and safety of Nivolumab Combined with Brentuximab Vedotin in a separate Mediastinal gray zone lymphoma cohort, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology